Tempus AI Stock Surges 39.5% on Merck-Moderna Trial Boost

A Sudden Repricing, Not a New Funding Round

Tempus AI's stock did something rare this week: it climbed 39.5% over five trading sessions while the broader market slid, with the S&P 500 down 1.9% and the Nasdaq Composite off 2.8% over the same stretch 6. The bulk of the move came in three explosive sessions — a 24.1% jump on Wednesday, an 8.8% gain on Thursday and a 9.1% advance on Friday — a pattern that stood out even against comparable diagnostics peers like Guardant Health, Natera and IQVIA, which posted far more modest gains 7. Despite the surge, Tempus shares remain roughly 10% below where they traded a year ago, a reminder of how volatile the stock has been since its 2024 debut 6.

The move was not tied to a fresh venture round or a new funding announcement. Instead, it was a public-market re-rating of a deal Tempus had already struck weeks earlier: its planned acquisition of cancer-genomics company Personalis 16.

The Spark: A Melanoma Vaccine Trial Hits Its Mark

The catalyst arrived Wednesday morning, when Merck and Moderna announced that their Phase 3 INTerpath-001 trial had met its primary endpoint. The study paired Moderna's individualized mRNA neoantigen therapy, intismeran autogene, with Merck's Keytruda, and showed a significant improvement in recurrence-free survival among melanoma patients who had undergone surgery 8. Analysts described it as the first successful Phase 3 readout ever recorded for a custom mRNA cancer treatment 8.

Tempus itself had no drug in that trial. The link to its stock ran through Personalis, the genomic tumor-profiling company whose NeXT Platform technology underpinned the vaccine program 68. Because Tempus had already agreed to acquire Personalis, traders effectively treated the trial's success as third-party validation of an asset Tempus was about to own outright. Tempus CEO Eric Lefkofsky underscored the connection publicly, congratulating Merck and Moderna on social media while noting the company's pride in supporting the program through its Personalis partnership 8.

Inside the Personalis Deal

Tempus first announced its agreement to acquire Personalis on July 20, offering $16.25 per share 91011. The transaction figures were described somewhat differently across outlets: Tempus's own materials framed the deal as roughly $1.5 billion in enterprise value net of its existing stake in Personalis 91014, while Bloomberg and Yahoo Finance cited a $1.7 billion equity valuation 1112. Both figures reflect legitimate but different ways of measuring the same transaction rather than a factual conflict.

The offer represented a 6% premium to Personalis's prior closing price and a steeper 28% premium to its unaffected 30-day volume-weighted average price 91014. Structurally, the deal is set up as an all-stock transaction, though Tempus retains the option to pay up to half the consideration in cash, funded through existing cash reserves and credit facilities 91014. Closing is expected in late 2026 or early 2027, pending shareholder and regulatory approval 111219.

Personalis brings Tempus its NeXT Personal minimal residual disease (MRD) test, a technology used to detect lingering traces of cancer after treatment. Tempus and Personalis have pointed to the MRD market as a more-than-$20-billion opportunity 91014. Personalis reported preliminary second-quarter revenue of $22.4 million and more than 10,000 clinical tests delivered in the quarter, with one account putting the figure precisely at 10,384 tests, a 33% sequential increase 1013. The two companies were not strangers before the deal: Tempus had invested in Personalis back in 2023 and had already been commercializing its MRD test, making this acquisition more a vertical consolidation than an entry into new territory 913.

From Skepticism to Enthusiasm

When the acquisition was first announced, investors were unconvinced. Tempus shares fell as much as 9.2% in the immediate aftermath, and some accounts put the initial decline in the 4% to 7% range 1215. The hesitation centered on dilution from an equity-heavy deal, a rich valuation — Needham pegged the price at roughly 15.5 times Personalis's estimated 2027 revenue — and a long runway to closing 15. A shareholder-rights firm also began reviewing the transaction, questioning whether Tempus's existing ownership stake and prior relationship with Personalis created conflicts unfavorable to Personalis shareholders 15.

The Merck-Moderna news flipped that narrative. Instead of looking like an expensive, dilutive bolt-on, the acquisition suddenly read as a well-timed purchase of infrastructure tied to a breakthrough personalized-cancer-treatment platform. One market analysis calculated that Tempus added roughly $3.03 billion in equity value across the two biggest rally sessions — more than double the stated $1.5 billion value of the Personalis deal itself 16. That gap suggests investors were pricing in an expanded opportunity across cancer monitoring and drug discovery, not simply marking the acquisition to a fair valuation 16.

Earnings Provided the Foundation

The rally landed on top of an already-improving fundamental picture. Tempus's second-quarter revenue reached $382.5 million, up 22% year over year, with diagnostics revenue of $289.3 million (up 20%) and data-and-applications revenue of $93.2 million (up 28%) 171819. The company posted GAAP net income of $5.6 million, compared with a $42.8 million loss a year earlier, and adjusted EBITDA of $8 million 181920. Management raised full-year 2026 revenue guidance to a range of $1.595 billion to $1.605 billion, implying roughly 25% growth, while maintaining adjusted EBITDA guidance of about $65 million 171819.

That quarterly profit carries caveats. It included $98.5 million in unrealized gains on marketable securities and $55.6 million in stock compensation and related payroll costs, while operating cash flow stayed negative at $7.5 million 19. MRD test volumes climbed to roughly 9,000 in the quarter, up from 6,500 previously, and the company's data-licensing arm, Insights, grew 36% — a sign of accelerating pharmaceutical demand for Tempus's clinical and molecular datasets, which by some accounts exceed 500 petabytes 71720.

Part of a Broader AI-Unicorn Story

Tempus is frequently grouped with AI unicorns because of its private-market history rather than any new funding news this week. Founded in 2015 by Groupon co-founder Eric Lefkofsky, the company raised more than $1 billion privately, including a 2020 round valuing it near $8.1 billion and roughly $200 million from SoftBank in 2024, before going public that June at $37 a share in an offering that raised $410.7 million against an implied $6.1 billion valuation. Precise lifetime fundraising totals vary by source, ranging from roughly $1.05 billion to $1.42 billion depending on methodology, underscoring that these are reasonable estimates rather than a single verified figure.

This week's action fits into a wider pattern of consolidation in health-tech and AI, echoing a moment when large, well-capitalized platforms are opting to acquire specialized genomics and data assets rather than build every capability from scratch — a dynamic visible elsewhere in AI dealmaking, from Nvidia's reported pursuit of Hugging Face 4 to SpaceX's closed acquisition of Cursor 5 and Stripe's purchase of OpenRouter 3.

What Still Needs to Be Proven

Tempus's rally reflects optimism about a future that has not yet been delivered. Detailed Phase 3 efficacy data from the Merck-Moderna trial have not been fully disclosed, and the Personalis deal still requires shareholder and regulatory sign-off, with a contractual provision letting Personalis terminate if Tempus shares fall below $46 16. Investors will be watching whether the acquisition closes on schedule, whether MRD testing converts into durable reimbursed revenue, and whether Tempus's quarterly profitability proves repeatable rather than a one-time accounting result. With the stock trading well above its 52-week midpoint and technical indicators flashing overbought signals, the coming quarters — not this week's headlines — will determine whether the re-rating holds.